Anaplastic Thyroid Cancer: New Horizons and Challenges

• Autores: Anastasios Maniakas, Mark Zafereo, Maria E. Cabanillas Cabanillas
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 51, Nº. 2, 2022, págs. 391-401
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Anaplastic thyroid cancer (ATC) remains a highly aggressive and deadly disease, requiring rapid referral to a highly specialized center BRAF mutation status must be obtained rapidly to determine BRAF/MEK inhibitor eligibility Enrollment in clinical trials may offer the best chance for survival and overall quality of life to a patient with ATC With the advent of novel therapeutics and rapid/favorable response to systemic therapy, patients with initial locoregional and/or metastatic disease may become eligible for surgery